Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Aug 26, 2021	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0001209191-21-053466.pdf 0001209191-21-053466.rtf 0001209191-21-053466.xls View HTML
Jan 12, 2022	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0001209191-22-003012.pdf 0001209191-22-003012.rtf 0001209191-22-003012.xls View HTML
Jun 27, 2022	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0000899243-22-024202.pdf 0000899243-22-024202.rtf 0000899243-22-024202.xls View HTML
May 05, 2023	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0001209191-23-027832.pdf 0001209191-23-027832.rtf 0001209191-23-027832.xls View HTML
Jun 01, 2023	25-NSE	25-NSE	Other	0001354457-23-000372.pdf 0001354457-23-000372.rtf 0001354457-23-000372.xls View HTML
Jun 12, 2023	15-12G	15-12G	Other	0001104659-23-070143.pdf 0001104659-23-070143.rtf 0001104659-23-070143.xls View HTML
May 13, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001750019-19-000036.pdf 0001750019-19-000036.rtf 0001750019-19-000036.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT View HTML
Aug 09, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001750019-19-000046.pdf 0001750019-19-000046.rtf 0001750019-19-000046.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT View HTML
Nov 12, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-19-042612.pdf 0001564590-19-042612.rtf 0001564590-19-042612.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 14, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-20-025260.pdf 0001564590-20-025260.rtf 0001564590-20-025260.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.